Cytodyn Inc (CYDY)

[stockorus]

In CD12, the results indicated positive efficacy for Critical patients but were more or less ambiguous about the other severe patients.

Still we are once again doing a large trial in Brazil aimed at severe patients, instead of focusing our resources on the critical subpopulation.

Is this a "just in case" strategy, where Cytodyn still hopes LL would work well for severe patients if tested in a larger population? Did Nader give insight into why (apart from greater revenue if successful) they decided to also do the severe trial in Brazil? Is there some way to focus the protocol so that we can better select severe patients for whom LL will work better?

It would have been hard to make a case for this new trial with the US FDA based on the CD12 results for severe patients.